R41/R42 Small Business Technology Transfer Grant (STTR), R43/R44 Small Business Innovation Research Grants (SBIR)
SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance (SB1)
The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies that benefit society. The main objective in SBIR/STTR Phase I is to establish the technical merit and feasibility of the proposed research and development (R&D) efforts, whereas in SBIR/STTR Phase II and Phase IIB it is to continue the R&D efforts to advance the technology toward ultimate commercialization. At the conclusion of an SBIR/STTR Phase II or Phase IIB award, it is expected that the SBC will fully commercialize their product or technology using non-SBIR/STTR funds in Phase III. Some projects initiated with SBIR or STTR funding require support beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap, known as the “Valley of Death,” between the end of the SBIR/STTR Phase II award and the commercialization stage. A number of NIH Institutes and Centers (ICs) participate in the Phase IIB program, which provides additional support to mitigate the funding gap with a second Phase II award. However, Phase IIB programs are limited in the amount of outsourcing allowed and some projects require technical assistance that is typically outsourced to contract research organizations (CROs) (e.g. regulatory assistance). In addition, SBIR/STTR awards may not support activities important for commercialization, such as product development and market planning, market research, and costs related to license agreements and partnerships.
The SBIR/STTR Programs were recently reauthorized by the United States Congress with the SBIR/STTR Reauthorization Act of 2011 (P.L. 112-81). Part of the reauthorization was an expansion of the Commercialization Readiness Pilot (CRP) Program to the NIH and this funding opportunity announcement (FOA) aims to implement the CRP Program at NIH and CDC. The goal of this FOA is to facilitate the transition of previously funded SBIR/STTR Phase II projects to the commercialization stage by providing additional support for later stage technical assistance activities not typically supported through Phase II or Phase IIB grants or contracts. Only those applicants who have recently received Phase II or Phase IIB funding from one of the participating NIH Institutes/Centers or CDC are eligible for this program, as described in Section III.1. CRP awards are considered Type 2 "Renewals" of Phase II or IIB SBIR/STTR awards.
|Full Announcement||PAR-16-026 |
|Notice(s) for this Opportunity|
NOT-OD-16-004 - NIH & AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for 2016 Grant Applications (November 18, 2015)
November 10, 2015 - Notice of Correction to Award Budget in PAR-16-026. See Notice NOT-HL-15-283.
|Letter of Intent Due Date|
30 days prior to the application due date
|Application Due Date|
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.